Disease details

臨床試験数 : 3,342 / 薬物数 : 2,355 - (DrugBank : 406) / 標的遺伝子数 : 269 - 標的パスウェイ数 : 241

5 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-jRCT2051210146	24/02/2022	26/12/2021	Phase 3 Study to Evaluate Efficacy, Safety, PK, and PD of SC Natalizumab in Japanese Participants With RRMS	A Single-Arm, Open-Label, Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered to Japanese Participants With Relapsing-Remitting Multiple Sclerosis via a Subcutaneous Route of Administration	Relapsing-Remitting Multiple Sclerosis	Participants will receive natalizumab 300 mg SC Q4W for 48 weeks.	Amir Hadi Maghzi	NULL	Pending	>= 18age old	<= 65age old	Both	20	Phase 3	Japan
2	JPRN-UMIN000043910	2021/06/01	01/06/2021	Association between brain atrophy and intestinal permeability in patients with multiple sclerosis	Association between brain atrophy and intestinal permeability in patients with multiple sclerosis - Brain atrophy and intestinal permeability in MS	multiple sclerosis	A standard solution of lactulose (5 g) and mannitol (2 g)in 500 mL of tap water was ingested before bed. Urine was collected the following morning in a container (with 5 mL of thymol solution).	Department of Neurology and Neurological Science, Tokyo Medical and Dental University	NULL	Pending	18years-old	80years-old	Male and Female	40	Not selected	Japan
3	ChiCTR2100043013	2021-01-31	2021-02-04	Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD	Efficacy difference between low dose rituximab and mycophenolate mofetil in preventing recurrence of NMOSD	Neuromyelitis optica spectrum diseases	low dose rituximab group: low dose rituximab ;mycophenolate mofetil group:mycophenolate mofetil ;	Shandong University Qilu Hospital	NULL	Pending			Both	low dose rituximab group:30;mycophenolate mofetil group:30;	Phase 4	China
4	ChiCTR2000034098	2020-07-01	2020-06-23	A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research	A New Quantitative Method Used to Evaluate Cervical Spinal Cord Damage in Multiple Sclerosis: Diffusional Kurtosis Imaging Research	Multiple Sclerosis	Gold Standard:Conventional cervical MRI;Index test:Diffusional Kurtosis Imaging;	The First Hospital of Jilin University	NULL	Pending			Both	Target condition:48;Difficult condition:0		China
5	EUCTR2011-000985-36-ES (EUCTR)	22/02/2013	25/01/2012	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Study on the Use of surface electromyography in the detection of objective differencies in patients with spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex	Spasticity due to multiple sclerosis identified as responders and not responders under treatment with Sativex MedDRA version: 14.1;Level: LLT;Classification code 10041416;Term: Spasticity;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]	Trade Name: SATIVEX Product Name: sativex Product Code: N02BG10 INN or Proposed INN: pending Other descriptive name: CANNABIDIOL	JOSE MANUEL GARCIA DOMINGUEZ	NULL	Not Recruiting			Female: yes Male: yes			Spain

先頭へ